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Abstract
Background: Laparoscopy-assisted vaginal hysterectomy is one of the definite methods for the
treatment of symptomatic uterine fibroids with lesser intraoperative bleeding and shorter
hospitalization compared with abdominal hysterectomy. However, laparoscopy-assisted vaginal
hysterectomy cannot preserve uterus and can show postoperative complications by the change of
pelvic structure. Thus, laparoscopic uterine artery ligation has been introduced for relieving the
symptoms caused by uterine fibroids in place of hysterectomy. The current study was designed to
compare postoperative quality of life between laparoscopic uterine artery ligation and laparoscopy-
assisted vaginal hysterectomy, and to evaluate the efficacy of laparoscopic uterine artery ligation
which can treat symptomatic uterine fibroids with the preservation of uterus.
Methods and design: Patients enrolled the current study are randomized to laparoscopic uterine
artery ligation or laparoscopy-assisted vaginal hysterectomy. The primary outcome is to compare
postoperative quality of life between laparoscopic uterine artery ligation and laparoscopy-assisted
vaginal hysterectomy using the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire for Cancer patients version 3.0. Secondary outcomes are to evaluate
the volume reduction of uterus, uterine fibroids and ovaries by the 2 treatments, to compare the
improvement of subjective symptoms using 11-point symptom score and postoperative clinical
outcomes between laparoscopic uterine artery ligation and laparoscopy-assisted vaginal
hysterectomy, and to investigate the improvement of postoperative vaginal bleeding by
laparoscopic uterine artery ligation.
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Discussion: Among treatment methods for symptomatic uterine fibroids with the preservation of
uterus, laparoscopic uterine artery ligation is expected to have the efficacy like uterine artery
embolization, which appeared to be safe for routine use with symptomatic relief. The current study
fully recruited in June 2008 and the results will be available in June 2009. If there is no difference of
postoperative QOL between laparoscopic uterine artery ligation and laparoscopy-assisted vaginal
hysterectomy for the treatment of symptomatic uterine fibroids, the comparison of quality of life
between laparoscopic uterine artery ligation and uterine artery embolization will be also needed as
a surgical treatment for preserving uterus.
Trial registration: Current Controlled Trials ISRCTN76790866
Background
Uterine fibroids are the most common benign uterine
tumors. They may be more common in women who are
obese, and there appears to be an increased familial inci-
dence [1]. Although fewer than one half of them are esti-
mated to produce symptoms [2], uterine fibroids may
cause different symptoms including menorrhagia, inter-
mittent menstrual bleeding, pelvic pain, urinary fre-
quency and constipation.
The management of uterine fibroids is dependent on the
patient's age and proximity to anticipated menopause,
symptoms, patient preference, and the experience and
skills of the clinician. Although non-surgical treatment
using gonadotropin-releasing hormone (GnRH) agonist
is effective for reducing the size and symptoms of uterine
fibroids, surgical treatment is also needed for patients
with potential indications such as abnormal uterine
bleeding unresponsive to hormone, urinary symptoms or
signs such as hydronephrosis and infertility with uterine
fibroids as the only abnormal finding.
Among surgical treatments, hysterectomy is a definite
method for the treatment of symptomatic uterine
fibroids. Especially, laparoscopy-assisted vaginal hysterec-
tomy (LAVH) has more advantages including lesser intra-
operative bleeding and shorter hospitalization than
abdominal hysterectomy [3]. However, LAVH cannot pre-
serve uterus and can show postoperative complications by
the change of pelvic structure [4].
Thus, laparoscopic uterine artery ligation (LUAL) has
been introduced in 2001 as an alternative technique for
treating uterine fibroids, and significant reduction in the
dominant fibroid size (average, 76%) and the uterine vol-
ume (average, 46%) were sonographically demonstrated
[5]. Thereafter, some studies have reported that LUAL may
be effective in relieving the symptoms caused by uterine
fibroids, and this procedure can be used in place of hyster-
ectomy [6,7]. Although of these results, there is no study
for the comparison of postoperative quality of life (QOL)
between LUAL and LAVH.
The current study has been designed to compare the post-
operative QOL between LUAL and LAVH, and to evaluate
the efficacy of LUAL which can treat symptomatic uterine
fibroids with the preservation of uterus.
Methods and design
Study design
This is a multi-center randomized controlled trial compar-
ing postoperative QOL between LUAL and LAVH for the
treatment of symptomatic uterine fibroids. Eligible
patients were randomized in a 1:2 ratio to undergo either
LAUL or LAVH.
Primary outcome
Postoperative QOL 12 months after surgical treatment are
evaluated using the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire for
Cancer patients (EORTC QLQ-C30) version 3.0., which
has been validated to the simplified Korean version [8].
After the evaluation of postoperative QOL, the results will
be compared between LUAL and LAVH.
Secondary outcomes
Volume reduction of uterus, uterine fibroids and ovaries by USG
The volume reduction of uterus, uterine fibroids and both
ovaries is evaluated in patients treated with LUAL,
whereas the volume reduction of only both ovaries is
examined in those treated with LAVH.
Improvement of subjective symptoms11-point symptom
score, ranging from -5 (markedly worse) to +5 (markedly
better), is a method for evaluating either improvement or
aggravation of symptoms which patients have, for exam-
ple, menorrhagia, pain, gastrointestinal discomfort, etc
[9]. It is applied in all patients for evaluating the improve-
ment of subjective symptoms by surgical treatment.
Evaluation of postoperative vaginal bleeding
In patients treated with LUAL, postoperative vaginal
bleeding is measured using a simple visual assessment
technique [10]. It is measured monthly by use of the
recording sheet including simple visual assessment tech-
nique by herself.Trials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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Postoperative clinical outcomes
Compared with preoperative status, postoperative clinical
outcomes are compared between LUAL and LAVH as fol-
lows: anemia, hormonal status and serum CA-125 levels;
operation time, hospitalization and recovery time to rou-
tine life; postoperative pain; conversion to laparotomy;
satisfaction of postoperative sexual intercourse; complica-
tions associated with surgery.
Eligibility
Inclusion criteria
• Age ≥ 40 years
￿ Premenopausal patients
￿ Patients who do not want conception any more
￿ Patients who agree to the current study protocol with
informed consent
￿ Patients with more than 2 cm sized uterine fibroids on
ultrasonography (USG)
￿ Patients with symptomatic uterine fibroids such as men-
orrhagia, dysmenorrhea, lower abdominal discomfort or
pain, lower back pain and urological symptoms including
dysuria and frequency
￿ Patients without underlying disease affecting QOL
￿ At least six months interval after last medication if
patients have been treated with GnRH agonists.
Exclusion criteria
￿ Age < 40 years
￿ Patients with subserosal pedunculated uterine fibroids
￿ Pregnant patients
￿ Patients with pelvic inflammatory disease (PID) devel-
oped within one month
￿ Patients with suspicious adenomyosis by USG
￿ Patients contraindicated by surgical treatment
￿ Patients with previous history of myomectomy, hyster-
ectomy, myolysis, uterine artery embolization
￿ Patients with underlying disease affecting QOL
￿ Less than six month's interval after last medication, if
patients have been treated with GnRH agonist
Interventions
Laparoscopic uterine artery ligation
After peril-umbilical tracer puncture and the infusion of
CO2 gas, 2 or 3 tracer punctures are made additionally.
Entering the peritoneal cavity, bilateral mesosalpinges
including ovarian vessels are coagulated and ligated using
hemoclips. Thereafter, right broad ligament is incised
between right round ligament and fallopian tube, and the
retroperitoneal space is exfoliated using non-traumatic
forceps. After right internal iliac artery is seen, the branch
of the artery, right uterine artery, is identified. Bipolar
coagulation followed by the ligation using hemoclips is
applied to right uterine artery. Left uterine artery is ligated
according to the procedure for right uterine artery ligation.
Laparoscopy-assisted vaginal hysterectomy
After peri-umbilical trocar puncture and the infusion of
CO2 gas, 2 or 3 trocar punctures are made additionally.
Entering the peritoneal cavity, bilateral round ligaments,
ovarian ligaments and fallopian tubes are ligated. The
uterus is pulled down into the operative field by traction
on the each lateral side of the cervical lip. The initial trans-
verse incision through the anterior vaginal wall is made at
the cervicovaginal junction and extended laterally on both
sides to form encircling incision. The bladder is dissected
off the cervix and lower uterine segment anteriorly, and
bilateral bladder pillars are ligated. The exfoliation of
bladder is advanced to the point where the vesicouterine
(U-V) fold is seen, and the U-V fold is incised transversely
and the peritoneal cavity is opened. The posterior vaginal
wall is dissected off the cervix to the peritoneal reflection
of the cul-de-sac. Bilateral cardinal ligaments, uterine ves-
sels and uterosacral ligaments are ligated, and thereby the
uterus is delivered through the anterior fornix using tenac-
ulum.
Outcome measurements
Primary outcome
After patients are enrolled and randomized, we interview
them using EORTC QLQ-C30 before surgical intervention
for the evaluation of preoperative QOL. Since the validity
of the EORTC QLQ-C30 has already been demonstrated
in Republic of Korea [8], and the authors responsible for
the validation recommended its usefulness in the current
study, we decided to apply it for the evaluation of postop-
erative QOL in patients with symptomatic uterine
fibroids.
The EORTC QLQ-C30 is a 30-item core-cancer-specific
questionnaire-integrating system for assessing the health-
related QOL in patients participating in international clin-
ical trials [11]. The questionnaire incorporates five func-
tional scales (physical, role, cognitive, emotional, and
social), three symptom scales (fatigue, pain, and nausea
and vomiting), a global health and QOL scale, and singleTrials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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items for the assessment of additional symptoms com-
monly reported by cancer patients (e.g., dyspnea, appetite
loss, sleep disturbance, constipation, and diarrhea), as
well as the perceived financial impact of the disease and
treatment [12]. All items are scored on 4-point Likert
scales, ranging from 1 ('not at all') to 4 ('very much'), with
the exception of two items in the global health/QOL scale
which use modified 7-point linear analog scales [11].
After 12 months, all enrolled patients will be interviewed,
and the results of EORTC QLQ-C30 will be compared
with preoperative results of it (Fig. 1).
Secondary outcomes
Volume reduction of uterus, uterine fibroids and bilateral ovaries by 
USG
The method for evaluating volumes of uterus, uterine
fibroids and ovaries is as follows: Volume (cm3) = maxi-
mal sagittal diameter (length, cm) × maximal coronal
diameter (width, cm) × maximal antero-posterior diame-
ter (depth, cm) × 0.5233 [13]. Volumes of uterus and uter-
ine fibroids are evaluated in patients treated with LUAL
preoperatively and every 3 months, whereas volumes of
bilateral ovaries are examined in all patients preopera-
tively and every 6 months (Fig. 2).
Improvement of subjective symptoms
11-point symptom score are evaluated in all patients 12
months after surgery. Symptoms by uterine fibroids are
divided as follows; vaginal bleeding: pelvic pain: urologic
symptom; gastrointestinal symptom; other symptoms
(Fig. 3). After the completion of the current study, the
results are compared between LUAL and LAVH.
Evaluation of postoperative vaginal bleeding
We have made "Bleeding Chart Score" by use of a simple
visual assessment technique (Fig. 4) [10]. After we educate
patients treated with LUAL, in particular, patients with
preoperative symptoms such as menorrhagia and inter-
mittent vaginal bleeding, about a simple visual assess-
ment technique, they should record the amount of
vaginal bleeding using the technique by her monthly.
Thereafter, we calculate and record the amount of vaginal
bleeding in the Bleeding Chart Score. After the comple-
tion of the current study, we will analyze the change of the
amount of vaginal bleeding between preoperatively and
12 months after surgery.
Postoperative clinical outcomes
1) Anemia, hormonal status and serum CA-125 levels
Serum hemoglobin levels are evaluated in acute and
chronic phases. In the acute phase, we check serum hemo-
globin levels preoperatively and 2 days after surgery for
comparing the effect of intraoperative blood loss between
LUAL and LAVH. In the chronic phase, we check serum
hemoglobin levels every 6 months, and we will compare
serum hemoglobin levels between the 2 treatment meth-
ods.
The evaluation of hormone status is important because
Liu et al [5] have reported that 3.5% of patients presented
with elevated FSH, suggesting that LUAL can affect preop-
erative hormonal status. Moreover, serum CA-125 levels
are increased in uterine fibroids, whereas they are
decreased after the treatment of uterine fibroids. It means
that serum CA-125 levels may be one of indirect markers
reflecting the change of uterine fibroids [14]. Thus, serum
LH, FSH, E2 and CA-125 levels are checked preoperatively
and every 6 months, and we will compare these values
between the 2 treatment methods.
2) Operation time, hospitalization and recovery time to
routine life
The operation time is recorded in all patients for the inves-
tigation of whether there is a significant difference in the
time between LAUL and LAVH. All patients are discharged
as soon as possible if they are considered not to be hospi-
talized, and we will evaluate hospitalization and recovery
time to routine life in all patients because the 2 parame-
ters may reflect the time from surgery to healthy status.
3) Postoperative pain
Pain intensity is measured with a visual analogue scale
(VAS), a 100-mm horizontal line with anchors of no pain
and worst possible pain. The VAS is scored by measuring
in millimeters the distance from the side marked no pain
to the edge of the mark made by the patient. Possible
scores ranges from a minimum of 0 to a maximum of 100
mm. The VAS scale is presented to the patients individu-
ally by instructed nurses who are unaware of assignments.
After the VAS scales are evaluated during postoperative 3
days, the sums of scores will be compared between LUAL
and LAVH.
4) Conversion to laparotomy
Although the 2 surgical treatments are similar in terms of
laparoscopic managements, LUAL can preserve uterus
with exploration of retroperitoneal space and ligation of
uterine artery. On the other hand, LAVH removes uterus
without the exploration of retroperitoneal space. Thus,
these differences can contribute the rate of conversion
from laparoscopic approach to laparotomy. We will com-
pare the rate of conversion to laparotomy between LUAL
and LAVH.
6) Satisfaction of postoperative sexual intercourseTrials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC  QLQ-C30) version 3.0. for comparing postoperative quality of life between laparoscopic uterine artery ligation and laparos- copy-assisted vaginal hysterectomy Figure 1
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer 
patients (EORTC QLQ-C30) version 3.0. for comparing postoperative quality of life between laparoscopic 
uterine artery ligation and laparoscopy-assisted vaginal hysterectomy.Trials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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Calculation of volumes of uterus, uterine fibroids and bilateral ovaries by use of transvaginal ultrasonography Figure 2
Calculation of volumes of uterus, uterine fibroids and bilateral ovaries by use of transvaginal ultrasonography.Trials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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Since patients treated with LUAL have cervices while those
treated with LAVH have no cervices postoperatively, types
of surgical treatment can affect postoperative sexual inter-
course. Thus, the change of satisfaction of sexual inter-
course will be evaluated after 12 months after surgery. The
satisfaction of sexual intercourse is scored on 3-point
scales, consisting of -1 ('not satisfied'), 0 ('no change') and
+1 ('satisfied').
7) Complications associated with surgery
We divided complications associated with surgery as fol-
lows: intraoperative complication; complication during
hospitalization; complication within 1 month; complica-
tion within 12 months. Moreover, the severity of the com-
plications is defined as follows [9].
(1) Grade 1: no consequence for the patients and necessi-
tated no or only nominal treatment (e.g. arterial spasm,
postpuncture hematoma, surgical wound hematoma, vag-
inal discharge, urinary retension, thigh paresthesia).
(2) Grade 2: necessitated non-life-threatening additional
treatment and had no sequelae of patients (e.g. urinary
infection, severe pelvic pain, renoureteral colic, vul-
vovaginitis, anal fissure).
(3) Grade 3: death or complication that represents a threat
to the patient's life or a source of permanent sequelae (e.g.
death, deep vein thrombosis, transfusion, intraabdominal
abscess, vesical fissure, surgical wound abscess).
After the completion of the current study, we will compare
these results between the 2 treatment methods.
11-point symptoms score for evaluating of postoperative symptoms 12 months after surgery Figure 3
11-point symptoms score for evaluating of postoperative symptoms 12 months after surgery.Trials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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Bleeding chart score by a simple visual assessment technique for evaluating vaginal bleeding in patients treated with laparo- scopic uterine artery ligation Figure 4
Bleeding chart score by a simple visual assessment technique for evaluating vaginal bleeding in patients 
treated with laparoscopic uterine artery ligation.Trials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
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Statistical analysis
We will analyze all patients assigned randomly. After
informed consent is obtained, blocked randomization is
performed by the Medical Research Collaborating Center
(MRCC), a central office, in Seoul National University Hos-
pital. The number of participants to be assigned to each of
the comparison groups is balanced within blocks. The cen-
tral office is remote from patient recruitment centers. Thus,
participants' details are provided by phone, and the alloca-
tion sequence is concealed to individual staffing in the cen-
tral office until a participant is irreversibly registered.
An intention-to-treat analysis will be performed as the
least biased way to estimate intervention effects in the cur-
rent study. For the primary endpoint, patients with miss-
ing EORTC-QLQ-C30 outcomes will be excluded from
analysis because they cannot be considered to show spec-
ified minimum outcomes of the intended intervention.
Analysis of covariance (ANCOVA) will be applied to com-
pare the QOL scores on the basis of EORTC QLQ-C30
between the 2 treatment methods, adjusting for baseline
values. After we consider the overall baseline EORTC
score, a level of p < 0.05 will be assumed that it indicates
imbalance. Thereafter, we will declare the variable to be
imbalanced, and then include baseline values of EORTC
QLQ-C30 in the ANCOVA to adjust the final results.
Other comparisons between the 2 groups will be made
with the use of a two-sided Student's t-test and the Mann-
Whitney U test for continuous data and the chi-square test
for categorical data. The original power calculation
requires the enrolled of a total 200 patients to give a
power of 90% to detect a difference of 10% in the EORTC
QLQ-C30 score at 12 moths (the primary outcome) at the
0.05 significance level.
All independent data such as serious adverse events and
recruitment rates will be reviewed by MRCC and the Insti-
tutional Review Boards (IRBs) in Seoul National Univer-
sity Hospital, Seoul National University Borame Hospital
and Seoul National University Bundang Hospital every 6
months. Moreover, the informal interim analysis for pre-
liminary results will be undertaken, which will inform us
whether the current study will be continued or not and
maintain the quality of data through balancing baseline
data.
Publication policy
The result of the current study will be submitted for pub-
lication to peer-review medical journals regardless of
whether the outcome is in favor of the objectives in the
current study.
Approval by the Institutional Review Board
We obtained the approval of the IRB of Seoul National
University College of Medicine/Seoul National University
Hospital for the current study in advance, and the IRB
number is H-0704-032-205.
Registration of clinical trial
The current study has been registered in the Current Con-
trolled Trials with the title "A randomized study of the
postoperative quality of life: Laparoscopic uterine artery
clipping versus laparoscopy-assisted vaginal hysterectomy
for the management of symptomatic uterine fibroids
(UTAC trial)" (Trial No. ISRCTN 6790866) [15].
Trial timetable
Trial start
July, 2007
Trial recruitment completed
June, 2008
Trial end
June, 2009
Trial duration
2 years
Duration of each patient's participation
1 year
Discussion
The current study has been designed to compare postop-
erative QOL between LAUL and LAVH, and to show the
similar efficacy of LAUL, compared with LAVH, for the
treatment of symptomatic uterine fibroids. Except for
LUAL, there are other surgical methods for the treatment
of symptomatic uterine fibroids as follows.
Firstly, myomectomy can be performed for reproductive
women with uterine fibroids as a cause of infertility and
patients with symptomatic uterine fibroids who want to
preserve uterus. Although many clinicians have suggested
that myomectomy might have more chance of intraoper-
ative bleeding and postoperative transfusion than hyster-
ectomy, some studies have shown that there is no
difference of bleeding and transfusion between myomec-
tomy and hysterectomy [16,17]. However, myomectomy
can lead to pelvic adhesion which may inhibits concep-
tion, and the rate of recurrence is up to 50%. Thus, one
third of all patients are known to undergo re-operation for
the treatment of uterine fibroids [18].
Secondly, myolysis had been introduced in 1993 as an
alternative method for treating symptomatic uterine
fibroids. Moreover, it can be performed by laparoscopy or
transvaginal approach using thermomyolysis by Nd:YAG
laser, cryomyolysis and myoma interstitial thermo-ther-
apy. Although the size of uterine fibroids has been
reported to decrease by 30–50%, severe pain by necrosisTrials 2009, 10:8 http://www.trialsjournal.com/content/10/1/8
Page 10 of 11
(page number not for citation purposes)
of them, uterine rupture during pregnancy, uterine
abscess and pelvic adhesion can be developed [19,20].
Thirdly, uterine artery embolization (UAE) has also been
introduced in 1995 for treating symptomatic uterine
fibroids [21]. Early analysis of an open, prospective, vol-
untary U.S. registry including 3,160 of patients revealed
major complications in 5.5% of patients at 30 days, with
0.1% requiring a hysterectomy [22]. Moreover, the
National Institute for Health and Clinical Excellence
issued guidelines in October 2004, starting that the proce-
dure appeared to be safe for routine use and that the
majority of patients have short-term symptomatic relief
[23]. However, the technique has some limitations such
as postembolization syndrome, the time required to per-
form the procedure, and radiation exposure for prevent-
ing the widespread application.
Thus, LUAL can be efficient for the treatment of sympto-
matic uterine fibroids, overcoming the complications of
UAE. Nevertheless, there is a need for careful assessment
of the effects of the procedure on QOL, particularly in
comparison with hysterectomy, especially, LAVH.
In conclusion, the current study is meaningful in that we
can suggest the results of the comparison of postoperative
QOL between LUAL and LAVH. If there is no difference of
postoperative QOL between the 2 treatment methods for
the treatment of symptomatic uterine fibroids, the com-
parison of QOL between LUAL and UAE will be also
needed as a surgical treatment for preserving uterus.
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